The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zelenay, S.
Right arrow Articles by Demengeot, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zelenay, S.
Right arrow Articles by Demengeot, J.
The Journal of Immunology, 2006, 177: 2036-2037.
Copyright © 2006 by The American Association of Immunologists


LETTERS TO THE EDITOR

Comment on "Cutting Edge: Anti-CD25 Monoclonal Antibody Injection Results in the Functional Inactivation, Not Depletion, of CD4+CD25+ T Regulatory Cells"

Santiago Zelenay and Jocelyne Demengeot

Instituto Gulbenkian de Ciência, Oeiras, Portugal

The injection of anti-CD25 mAb to deplete CD25+ regulatory T cells (TR) in mice has been common practice to infer the function of TR. In a recent report, Kohm et al. (1) claimed that injection of anti-CD25 mAb in mice results in the functional inactivation, not depletion, of CD4+CD25+ TR. This conclusion was based on the analysis of mice that received the rat-IgM 7D4 mAb or the rat IgG PC61. CD25 and FOXP3 expression was determined by FACS analysis after 7D4 treatment but solely by RT-PCR after PC61 administration (1). Using FACS analysis in both cases, we enumerated CD4+CD25+ and CD4+FOXP3+ cells in blood, spleen, and lymph nodes isolated from mice treated with either 7D4 or PC61 (Fig. 1). Similarly to Kohm et al., we found that despite the disappearance of surface CD25 expression, FOXP3+ cell frequency is not affected by 7D4 administration, irrespective of the tissue analyzed and independently of the dose used (up to 3 mg/mouse). In contrast, injection of as little as 500 µg/mouse of PC61 resulted in both the disappearance of CD25+ cells and the loss of CD4+FOXP3+ cells. In PBL, the frequency of CD4 cells expressing FOXP3 is reduced from an average of 8 to 3%, indicating that >65% of the total FOXP3+ cells are depleted. The disappearing cells are the bulk of the FOXP3+CD25+ TR, while the pre-existing FOXP3+CD25 subset appeared maintained. In spleen, ~45% of the FOXP3+ cells were depleted. TR originally CD25+ that lost CD25 expression and pre-existing CD25 TR appeared to contribute equally to the remaining FOXP3+ cell pool. In lymph nodes, depletion was less marked and corresponded to the disappearance of 33% of the FOXP3+CD25+. Increasing the amount of PC61 injected (up to 3 mg/mouse) did not dramatically increase the depletion efficiency (data not shown). We conclude that injection of the rat-IgG PC61 mAb, which has been the most frequently used to interfere with TR function in vivo, does result in depletion of a large fraction of TR.


Figure 1
View larger version (37K):
[in this window]
[in a new window]
 
FIGURE 1. C57BL/6 mice (8 wk old) raised in specific pathogen-free conditions were injected i.p. once with anti-CD25 mAb clone 7D4 (3 mg) or PC61 (500 µg). Splenocytes, lymph node cells, and PBL were isolated 3 days after from either control or treated mice and analyzed by flow cytometry for CD4, FOXP3, and CD25 expression (for CD25 visualization, clone 7D4 or PC61 was used when PC61 or 7D4 was injected, respectively). A, Representative staining of splenocytes (gated on CD4+ cells) analyzed for CD25 and FOXP3 expression. Number inside dot plots represents average ± SD of the percentage of FOXP3+ among CD4+ cells. B, Percentage of FOXP3+CD25+ ({blacksquare}) and FOXP3+CD25 ({square}) among CD4+ cells. **, p < 0.01 for CD4+FOXP3+ in PC61-injected mice vs control or 7D4-injected mice. Data represent the average ± SD for each group (n = 3). One of three independent experiments is shown.

 
This work was supported by the Fundação para a Ciência a Tecnologia-Programa Operacional Ciência Tecnologia e Inovação national programs.

References

  1. Kohm, A. P., J. S. McMahon, J. R. Podojil, W. S. Begolka, M. DeGutes, D. J. Kasprowicz, S. F. Ziegler, S. D. Miller. 2006. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J. Immunol. 176: 3301-3305. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Exp. Med.Home page
S. Piconese, B. Valzasina, and M. P. Colombo
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
J. Exp. Med., April 14, 2008; 205(4): 825 - 839.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Guilliams, G. Oldenhove, W. Noel, M. Herin, L. Brys, P. Loi, V. Flamand, M. Moser, P. De Baetselier, and A. Beschin
African Trypanosomiasis: Naturally Occurring Regulatory T Cells Favor Trypanotolerance by Limiting Pathology Associated with Sustained Type 1 Inflammation
J. Immunol., September 1, 2007; 179(5): 2748 - 2757.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. N. Couper, D. G. Blount, J. B. de Souza, I. Suffia, Y. Belkaid, and E. M. Riley
Incomplete Depletion and Rapid Regeneration of Foxp3+ Regulatory T Cells Following Anti-CD25 Treatment in Malaria-Infected Mice
J. Immunol., April 1, 2007; 178(7): 4136 - 4146.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Dai, B. Liu, S. M. Ngoi, S. Sun, A. T. Vella, and Z. Li
TLR4 Hyperresponsiveness via Cell Surface Expression of Heat Shock Protein gp96 Potentiates Suppressive Function of Regulatory T Cells
J. Immunol., March 1, 2007; 178(5): 3219 - 3225.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. P. Kohm and S. D. Miller
Response to Comment on "Cutting Edge: Anti-CD25 Monoclonal Antibody Injection Results in the Functional Inactivation, Not Depletion, of CD4+CD25+ T Regulatory Cells"
J. Immunol., August 15, 2006; 177(4): 2037 - 2038.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zelenay, S.
Right arrow Articles by Demengeot, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zelenay, S.
Right arrow Articles by Demengeot, J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS